Russell E Ware
Ware, Russell E.
VIAF ID: 26388164 (Personal)
Permalink: http://viaf.org/viaf/26388164
Preferred Forms
-
100 0 _
‡a
Russell E Ware
-
100 1 0
‡a
Ware, Russell E.
-
100 1 _
‡a
Ware, Russell E.
-
100 1 _
‡a
Ware, Russell E.
-
100 1 _ ‡a Ware, Russell E.
-
100 1 _ ‡a Ware, Russell E.
4xx's: Alternate Name Forms (3)
Works
| Title | Sources |
|---|---|
| Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes |
|
| Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia |
|
| Hemoglobin variants identified in the Uganda Sickle Surveillance Study |
|
| Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). |
|
| Hydroxyurea: Analytical techniques and quantitative analysis. |
|
| Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS) |
|
| Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? |
|
| Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation |
|
| Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease |
|
| Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin |
|
| Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model |
|
| Hydroxyurea to lower TCD velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort |
|
| IgA-mediated autoimmune hemolytic anemia in an infant |
|
| Interpretation of fetal hemoglobin only on newborn screening for hemoglobinopathy |
|
| Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease |
|
| Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study |
|
| Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial |
|
| Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members |
|
| Microarray analysis of liver gene expression in iron overloaded patients with sickle cell anemia and beta-thalassemia |
|
| Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management |
|
| The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia |
|
| Neurocognitive development of young children with sickle cell disease through three years of age. |
|
| Newborn Screening With Sickle Cell Point of Care: A Valuable Resource in Low-Income Settings |
|
| Novel use Of Hydroxyurea in an African Region with Malaria |
|
| Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial |
|
| Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics |
|
| Partial splenectomy for children with congenital hemolytic anemia and massive splenomegaly |
|
| Pediatric hematology |
|
| The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design |
|
| Pelger-Huët anomaly in a child with 1q42.3-44 deletion. |
|
| Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia |
|
| A pilot study of subcutaneous decitabine in β-thalassemia intermedia |
|
| Practice guideline for pulmonary hypertension in sickle cell: direct evidence needed before universal adoption |
|
| Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children |
|
| A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola |
|
| R2* magnetic resonance imaging of the liver in patients with iron overload |
|
| Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa |
|
| Reply to iManage: A novel self-management app for sickle cell disease. |
|
| RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia |
|
| Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia |
|
| Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. |
|
| Sickle-cell disease: an ounce of prevention, a pound of cure |
|
| Sickle cell screening in Europe: the time has come |
|
| Sickle cell screening in Uganda: High burden, human immunodeficiency virus comorbidity, and genetic modifiers |
|
| Simultaneous acute splenic sequestration and transient aplastic crisis in children with sickle cell disease |
|
| Stable-Isotope Dilution HPLC-Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples. |
|
| Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia |
|
| Stroke with Transfusions Changing to Hydroxyurea (SWiTHC), 2012 |
|
| Surveillance for sickle cell disease, United Republic of Tanzania |
|
| Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease |
|
| Thrombopoiesis: new ITP paradigm? |
|
| Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters |
|
| Transfusion support for patients with sickle cell disease, 1998: |
|
| Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention |
|
| Translating sickle cell guidelines into practice for primary care providers with Project ECHO. |
|
| UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia |
|
| Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG). |
|
| Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia |
|
| Your tired, your poor, your huddled masses |
|
| β-Thalassemia pathogenic variants in a cohort of children from the East African coast |
|
